SCHEMBL6031325

SCHEMBL6031325

COC(C(=O)O)c1ccn(Cc2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 12/20 0.46
CACNA1I Q9P0X4 12/20 0.46
CACNA1H O95180 11/20 0.46
HDAC1 Q13547 3/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 1/20 0.41
LDHB P07195 1/20 0.41
FAAH O00519 1/20 0.41
MGLL Q99685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034468 0.76 CACNA1G (0.48) CACNA1GCACNA1ICACNA1HHDAC1HDAC3
Hydrochloric Acid SCHEMBL6030024 0.76 KLKB1 (0.52)
SCHEMBL18367351 0.72 KMT2A (0.71) CACNA1GCACNA1ICACNA1HHDAC1HDAC3
SCHEMBL21070404 0.72 NPC1 (0.46) CACNA1GCACNA1ICACNA1HHDAC1HDAC3
SCHEMBL25834746 0.70 NPC1 (0.43) CACNA1GCACNA1ICACNA1HHDAC1HDAC3
SCHEMBL19659478 0.70 HDAC1 (0.56) CACNA1GCACNA1ICACNA1HHDAC1HDAC3
SCHEMBL18593147 0.70 CACNA1I (0.72) CACNA1GCACNA1ICACNA1HNPC1RAB9A
SCHEMBL27875012 0.69 CACNA1G (0.48) CACNA1GCACNA1ICACNA1HHDAC1HDAC3
SCHEMBL2485700 0.69 HDAC1 (0.58) CACNA1GCACNA1ICACNA1HHDAC1HDAC3
SCHEMBL8435270 0.69 HDAC1 (0.49) CACNA1GCACNA1ICACNA1HHDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1706396-A1 N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F.HOFFMANN-LA ROCHE AG (CH) 2006-10-04 EP disclosed
US-7056932-B2 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMAN-LA ROCHE INC. (US) 2006-06-06 US disclosed
WO-2005058868-A1 N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMANN-LA ROCHE INC. 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides F12, TFPI, F11 CACNA1G 1711/4885CACNA1I 1390/4885CACNA1H 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.